Bayer, Evotec ink research pact for kidney disease

Bayer's second research deal with Evotec could be worth as much as €300 million if certain milestones are hit. 

By Suzanne Elvidge • Sept. 23, 2016

Sonoco ThermoSafe buys Laminar Medica

The Illinois-based packing provider will acquire the UK-based pallet shipping producer to strengthen its shipping capabilities for biopharma companies.  

By Joe Cantlupe • Sept. 22, 2016

Genentech, BioNTech team up on cancer vaccines

Roche's cancer unit will pay a hefty $310 million upfront to access the German biotech's mRNA platform technology. 

By Lisa LaMotta • Sept. 22, 2016

PCT spears a cancer deal with Adaptimmune

The new agreement expands an existing collaboration between the two companies, and will cover cancer immunotherapy manufacturing. 

By Suzanne Elvidge • Sept. 22, 2016

Momenta, BioFactura team up on biosimilars

With a number of aging, yet still top-selling, biologics nearing patent expiry, biosimilar development in the U.S. is gaining steam. 

By Suzanne Elvidge • Sept. 22, 2016

Eleven Bio gets cancer focused with Viventia

A Phase 3 miss earlier this year led to major cutbacks in staff at Eleven Bio, which now attempts to reinvent itself through Viventia's pipeline. 

By Suzanne Elvidge • Sept. 22, 2016

GSK pledges to drop vax price for refugees

Discounts will apply at first only to Synflorix, the British drugmaker's pneumococcal vaccine. 

By Suzanne Elvidge • Sept. 21, 2016

Regeneron and Teva team up on long-mired painkiller

The biotech inks a deal with the Israeli company for its osteoarthritis drug. 

By Joe Cantlupe • Sept. 21, 2016

Allergan makes second acquisition in NASH space

The specialty pharma adds to its pipeline with back-to-back deals.

By Lisa LaMotta • Sept. 21, 2016

Madrigal sells off rights to cancer platform

Tarceva Therapeutics lined up milestones worth as much as $163M to secure global rights to Madrigal's drug conjugate program. 

By Suzanne Elvidge • Sept. 20, 2016

Allergan pays steep premium for Tobira and NASH drugs

Despite a recent trial miss for Tobira's lead drug, Allergan will pay six times the biotech's closing price Monday to get into the red-hot NASH space. 

By Ned Pagliarulo • Sept. 20, 2016

Dr Reddy's and Amgen broaden marketing collaboration

Under a 2015 partnership, Dr. Reddy's markets and distributes a number of Amgen drugs in India. An additional three drugs will now be covered by the agreement. 

By Suzanne Elvidge • Sept. 19, 2016

Rigel reorganization slashes 46 jobs

Restructuring the company around fostamatinib will save Rigel money but cost 38% of the workforce.

By Suzanne Elvidge • Sept. 16, 2016

OncoImmune locks up $250M antibody deal with Pfizer

Pfizer continues to build out its cancer portfolio, gaining access to OncoImmune's anti-CTLA4 mAb in a new licensing deal. 

By Suzanne Elvidge • Sept. 16, 2016

Takeda partners with PRA on drug development

About 300 Takeda employees have the option to move downstream to new positions at PRA in the U.S. and Europe. 

By Suzanne Elvidge • Sept. 15, 2016

Bayer lands $66B Monsanto deal

With the massive all-cash acquisition of the U.S. seed giant, the German pharma will significantly expand its agricultural sciences business. 

By Lisa LaMotta • Sept. 15, 2016

WellDoc, LifeScan join forces on digital diabetes partnership

The collaboration is aimed at improving care management for people with type 2 diabetes. 

By Suzanne Elvidge • Sept. 14, 2016

Allergan beefs up R&D with Vitae buy

The specialty pharma continues its bolt-on acquisition strategy, adding the dermatology-focused Vitae for $639 million. 

By Lisa LaMotta • Sept. 14, 2016

Catalent picks up Pharmatek, expanding West Coast reach

The CMO announced another acquisition, adding to its spray-dry capabilities and its geographic reach. 

By Lisa LaMotta • Sept. 13, 2016

Takeda terminates MacroGenics DART deal early

Despite Takeda realigning its priorities, MacroGeneics remains optimistic about further partnering. 

By Suzanne Elvidge • Sept. 13, 2016

GSK continues sell-off of non-core assets

The British pharma sold its anesthesia business for nearly $375 million.

By Lisa LaMotta • Sept. 12, 2016

Horizon adds rare disease drugs in $800M Raptor deal

The Irish specialty pharma will pay a small premium for Raptor, which markets Procysbi and Quinsair. 

By Ned Pagliarulo • Sept. 12, 2016

Sanofi, Verily launch Onduo for diabetes care

The big pharma teamed up with the Google subsidiary to launch a diabetes joint venture. 

By Lisa LaMotta • Sept. 12, 2016

Gilead comments on split rumors

Revenues from the big biotech's hepatitis C franchise have declined sharply, leading some to speculate the company could be worth more split in two. 

By Ned Pagliarulo • Sept. 8, 2016

Allergan picks up gene therapy company

Acquisition of RetroSense Therapeutics further builds out the Irish pharma's eye care portfolio. 

By Lisa LaMotta • Sept. 6, 2016